Suppliers / Shandong Xinhua Pharmaceutical

Shandong Xinhua Pharmaceutical

United States XIN.F 100 employees 2 duplicate records merged Updated 9 July 2026

Shandong Xinhua Pharmaceutical is an API manufacturer based in United States. It holds 42 active US drug master files across a filed portfolio of 17 molecules. Its filings concentrate with US FDA, MINSA (CR) and ARCSA (EC). Its GMP standing is certified by MFDS (Korea).

42
active US DMFs
0
valid CEPs
0
registered plants
10
filings across 5 regulators

What they file, and where

Molecule Regulators Docs
Acetylsalicylic Acid SFDA (Saudi Arabia), US FDA 5
Caffeine SFDA (Saudi Arabia), US FDA 4
Glimepiride US FDA 4
Hydrocortisone US FDA 4
Ibuprofen US FDA 4
Prednisone US FDA 4
Carbidopa SFDA (Saudi Arabia), US FDA 3
Levodopa SFDA (Saudi Arabia), US FDA 3
Calcium Polycarbophil US FDA 2
Meloxicam US FDA 2
Show all 17 molecules on file
Metamizole US FDA 2
Phenobarbital US FDA 2
Prednisolone US FDA 2
Sevelamer US FDA 2
Theophylline US FDA 2
Trimethoprim US FDA 2
Antipyrine SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 4 None
MINSA (CR) 3 None
ARCSA (EC) 1 None
EFDA (ET) 1 None
JFDA (JO) 1 None
MFDS (Korea) None 2

Comparing suppliers?

Choose your molecules and target markets. Shandong Xinhua Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates